The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

被引：0
|
作者：
He, Zhiyong
Lin, Jinghui
He, Yueming
Zhang, Jing
Yang, Dongyong
Qiu, Wenbin
Lai, Jinhuo
Chen, Xi
Fang, Wenzheng
Ye, Feng
Xu, Tianwen
Wu, Huita
Qiu, Dongfa
Chen, Wujin
Cai, Lifang
Chen, Shengchi
Lin, Qunying
Lin, Li
机构：
[1] Fujian Canc Hosp, Fuzhou, Peoples R China
[2] Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China
[3] Fujian Med Univ, Hosp Quanzhou Affiliated 1, Quanzhou, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Quanzhou, Peoples R China
[5] Fuding Hosp Fujian Prov, Fuding, Peoples R China
[6] Fujian Med Univ, Union Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[7] Fujian Med Univ, 900 Hosp, Joint Logist Team, Clin Med Coll, Fuzhou, Peoples R China
[8] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[9] Fujian Med Coll, Affiliated Hosp 2, Quanzhou, Peoples R China
[10] Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen, Peoples R China
[11] Fujian Med Univ, Sanming Hosp 1, Sanming, Peoples R China
[12] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[13] Fujian Med Univ, Affiliated Hosp, Putian City Hosp 1, Putian City, Peoples R China
[14] First Hosp Nanping, Nanping, Peoples R China
[15] Putian Univ, Affiliated Hosp, Putian, Peoples R China
[16] FuJian Med Univ, Zhangzhou Affiliated Hosp, Zhangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9030
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
    Chen, H.
    Hu, Y.
    Fan, Y.
    Wu, G.
    Cang, S.
    Yang, Y.
    Yang, N.
    Ma, R.
    Jing, G.
    Liu, A.
    Xu, X.
    Tang, S.
    Cheng, Y.
    Yu, Y.
    Wu, Y-L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S53 - S53
  • [2] Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial
    Yang, Lu
    Yang, Sheng
    Liu, Yutao
    Li, Junling
    Hu, Xingsheng
    Wang, Yalei
    Zhang, Yan
    Wang, Yan
    THORACIC CANCER, 2018, 9 (06) : 693 - 698
  • [3] The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Chin, Chun-Shih
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 434 - 444
  • [4] Stereotactic Body Radiotherapy Plus First-Line EGFR-TKIs for Patients with Advanced EGFR-Mutant Non -Small Cell Lung Cancer: A Meta -Analysis
    Yuan, Z.
    Tao, D.
    Zhou, W.
    Wu, Y. Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E85 - E85
  • [5] Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
    Hu, Di
    Zhou, Yan-Yan
    Ma, Hong-Bo
    Tao, Miao-Miao
    Huang, Qun-Zhen
    Yang, Zhen-Zhou
    Zhou, Qi
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [6] Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
    Di Hu
    Yan-Yan Zhou
    Hong-Bo Ma
    Miao-Miao Tao
    Qun-Zhen Huang
    Zhen-Zhou Yang
    Qi Zhou
    BMC Pulmonary Medicine, 23
  • [7] First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Wang, Shuyun
    Gao, Aiqin
    Liu, Jie
    Sun, Yuping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 443 - 453
  • [8] First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Shuyun Wang
    Aiqin Gao
    Jie Liu
    Yuping Sun
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 443 - 453
  • [9] Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
    Wang, Xiaohong
    Liu, Yonggang
    Meng, Zhiying
    Wu, Yun
    Wang, Shubin
    Jin, Gaowa
    Qin, Yingchun
    Wang, Fengyun
    Wang, Jing
    Zhou, Haifei
    Su, Xiaoxing
    Fu, Xiuhua
    Wang, Xiaolan
    Shi, Xiaoyu
    Wen, Zhenping
    Jia, Xiaoqiong
    Qin, Qiong
    Gao, Yongqiang
    Guo, Weidong
    Lu, Shun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [10] Aumolertinib plus anlotinib as first-line treatment for EGFR mutant non-small cell lung cancer: A phase II trial (ALWAYS)
    Chen, H. L.
    Chen, R.
    Xia, T.
    Huang, G.
    Luo, Y.
    Chen, H.
    Lin, M.
    Li, S.
    Yang, Z.
    ANNALS OF ONCOLOGY, 2024, 35
12345